All In Biotech

Drug Trial Radar · NCT02074579

A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome

A Phase 2, Single-center, Randomized, Double-Blinded, Placebo-Controlled Study on the Efficacy of Daikenchuto (TU 100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome

Last checked: Nov 19, 2026Latest source record: May 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Jul 2014

Primary completion

Apr 2016

Study completion Apr 2016

Sponsor

Lead sponsor
Tsumura USAIndustry
Sponsor type
Industry
Collaborators
ICON Clinical Research
First posted
Feb 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to assess the effect of orally administered TU-100 (5 g three times daily \[TID\]) as compared to placebo on abdominal bloating rating in female IBS patients.

Conditions

  • Irritable Bowel Syndrome in Females

Interventions

  • TU-100Drug

    15g daily, orally as 5g three times daily for 4 consecutive weeks

  • PlaceboDrug

    Matching placebo given 5g three times daily orally for 4 consecutive weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Abdominal bloating ratingTime frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Oppenheimer Family Center for Neurobiology of Stress Division of Digestive Diseases David Geffen School of Medicine at UCLA

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.